[Update on Kaposi's sarcoma].
Kaposi's sarcoma (KS) is a mesenchymal tumor involving blood and lymphatic vessels and induced by viral growth factors (HHV8-IL6). This article reviews the epidemiology, pathogenesis, clinical spectrum (classic KS, iatrogenic immunosuppressive KS, endemic African KS, and AIDS-KS), histological features, staging criteria and treatment of KS. Unlike industrialized countries that have benefited from widespread use of highly active antiretroviral therapy (HAART), developing countries continue to have a high incidence of AIDS-KS. Future therapeutic targets for KS are enhancement of immune function and treatment with angiogenesis inhibitors
Morand
J J
JJ
Service de dermatologie Médecin, HIA Laveran, Marseille, France. MorandJJ@aol.com
Lightburn
E
E
Simon
F
F
Patte
J H
JH
D003937:Diagnosis, Differential; D019353:Endemic Diseases; D015658:HIV Infections / Q000150:complications; D019288:Herpesvirus 8, Human / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D011379:Prognosis; D012514:Sarcoma, Kaposi / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy* / Q000821:virology; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy* / Q000821:virology